Cargando…

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis

BACKGROUND: The meta-analysis of randomized controlled trials has illustrated that the efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with standard-dose non-vitamin K antagonist oral anticoagulants, though they are still frequently prescribed for Asian patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ze, Zheng, Yingming, Li, Dandan, Wang, Xiaozhen, Cheng, Sheng, Luo, Xiao, Wen, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Society of Cardiology 2022
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361199/ https://www.ncbi.nlm.nih.gov/pubmed/35703478 http://dx.doi.org/10.5152/AnatolJCardiol.2022.1376

Ejemplares similares

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis
por: Hicks, Tim, et al.
Publicado: (2016)

Reply to Letter to the Editor: “How to Optimize Administration of Low-Dose NOACs in Everyday Practice?”
por: Li, Ze, et al.
Publicado: (2022)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Reversal agents for NOACs: Connecting the dots
por: Dalal, Jamshed, et al.
Publicado: (2016)

DVT prophylaxis in critical care: role of NOACS
por: Lancé, Marcus D.
Publicado: (2019)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
por: Piepiorka-Broniecka, Marta, et al.
Publicado: (2022)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding
por: Lee, Min-Taek, et al.
Publicado: (2020)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
por: Saviano, Angela, et al.
Publicado: (2022)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Warfarin dosing algorithms: A systematic review
por: Asiimwe, Innocent G., et al.
Publicado: (2020)

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?
por: Yang, Hayang, et al.
Publicado: (2017)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies
por: Chan, Yi-Hsin, et al.
Publicado: (2023)

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
por: Rizzo, Alessandro, et al.
Publicado: (2020)

High-dose versus low-dose angiotensin converting enzyme inhibitors in heart failure: systematic review and meta-analysis
por: Migliavaca, Celina Borges, et al.
Publicado: (2020)

Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis
por: Nochaiwong, Surapon, et al.
Publicado: (2016)

New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2018)

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
por: Altay, Servet, et al.
Publicado: (2017)

NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
por: Di Cesare, Mariachiara, et al.
Publicado: (2020)

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY
por: Köhler, Christina, et al.
Publicado: (2023)

Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications
por: Goette, Andreas, et al.
Publicado: (2023)

Effects of high-dose versus low-dose proton pump inhibitors for treatment of gastrointestinal ulcer bleeding: a meta-analysis of randomized controlled trials
por: Zhu, Wei, et al.
Publicado: (2022)

Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
por: Nunes, José Pedro L, et al.
Publicado: (2014)

Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials
por: Zhang, Jing-Zhan, et al.
Publicado: (2020)

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
por: Lin, Yi-Pin, et al.
Publicado: (2015)

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Publicado: (2020)

Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ca7s0uaj1fvj23pggvvtiqlep